Results 61 to 70 of about 28,054 (245)

Phos-tag analysis of Rab10 phosphorylation by LRRK2:a powerful assay for assessing kinase function and inhibitors [PDF]

, 2016
Autosomal dominant mutations that activate the leucine-rich repeat kinase-2 (LRRK2) cause inherited Parkinson's disease. Recent work has revealed that LRRK2 directly phosphorylates a conserved Thr/Ser residue in the effector-binding switch-II motif of a ...
Alastair D. Reith, Bras, Cherfils, Chia, Choi, Cooper, Daniels, Dario R. Alessi, Davies, Dzamko, Dzamko, Fell, Francesca Tonelli, Fraser, Fraser, Genta Ito, Gitler, Graham Duddy, Jaleel, Kinoshita, Kinoshita, Kinoshita, Koike, Kristina Katsemonova, Lai, Li, Li, Liu, MacLeod, Marco A.S. Baptista, Mata, Mata, Miller, Natalia Shpiro, Nichols, Paisan-Ruiz, Parisiadou, Pawel Lis, Pereira-Leal, Pfeffer, Philip Wing-Lok Ho, Pihlstrom, Reith, Sheng, Shu-Leong Ho, Singleton, Steger, Steve Wilson, Thaler, Tong, Tucci, West, Wiggin, Wilson, Zimprich   +54 more
core   +9 more sources

The function of Golgi apparatus in LRRK2-associated Parkinson’s disease

Frontiers in Molecular Neuroscience, 2023
Parkinson’s disease (PD) is a chronic neurodegenerative disease associated with the intracellular organelles. Leucine-rich repeat kinase 2 (LRRK2) is a large multi-structural domain protein, and mutation in LRRK2 is associated with PD.
Yonghang Wei, Maher un Nisa Awan, Liping Bai, Jie Bai   +3 more
doaj   +1 more source

Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson's Disease

Annals of Neurology, EarlyView.
Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people with Parkinson's disease (PD). We explored if free‐water (FW) imaging detects microstructural differences in the brains of patients with early PD with SAA+ or SAA– status.
Shannon Y. Chiu, Wei‐en Wang, Robin Chen, Jesse C. DeSimone, Derek B. Archer, Charles H. Adler, Shyamal H. Mehta, Sara R. Dresler, Melissa J. Armstrong, Nikolaus McFarland, Michael Okun, David E. Vaillancourt, Parkinson's Progression Markers Initiative, Neha Prakash, Tanya Simuni, Nabila Dahodwala, Caroline Tanner, Lana Chahine, Brit Mollenhauer, Anat Mirelman, Roy Alcalay; Katherine Leaver, Marie Saint‐Hilaire, Ruth Schneider, Christopher Tarolli, Werner Poewe, Aleksandar Videnovic, David Standaert, Marissa Dean, Sonja Jonsdottir, Rejko Krueger, Claire Pauly, Stewart Factor, Penelope Hogarth, Robert Hauser, Amy Amara, Michelle Fullard, Cyrus Zabetian, Hubert Fernandez, Kathrin Brockmann, Isabel Wurster, Yen Tai, Paolo Barone, Marina Picillo, Stuart Isaacson, Alberto Espay, Eduardo Tolosa, Javier Ruiz Martinez, Leonidas Stefanis, Kelvin Chou, Lorraine Kalia, Connie Marras, David Grimes, Tiago Mestre, Rajesh Pahwa, Mark Lew, Holly Shill, Shyamal Mehta, Giulietta Riboldi, Nikolaus McFarland, Ron Postuma, Zoltan Mari, David Ledingham, Nicola Pavese, Michele Hu, Norbert Brueggemann, Christine Klein, Bastiaan Bloem, Cristina Simonet, Alastair Noyce, Anette Janzen, David Pedrosa, Wolfgang Oertel, Njideka Okubadejo, David Shprecher, Arjun Tarakad, Emile Moukheiber, Joy Antala, Carla Aranda, Karen Williams, Sophia Melton, Karina Benson, Ashwini Ramachandran, Danielle Potts, Grace LaMoure, Ritikha Vengadesh, Ryan Manzler, Jaime Heller, Primi Ranola, Farah Kausar, Sherri Mosovsky, Diana Willeke, Elizabeth Kalinkara Gomez, Janelle Rodriguez, Nobuko Kemmotsu, May Eshel, Deborah Raymond, Abigail Desrosiers, Raymond James, Lauren Jackson, Iris Egner, Wesley Schlett, Courtney Blair, Lauren Ruffrage, Berenice Sevilla, Barbara Sommerfeld, Dustin Le, Erica Botting, Gabriella Mazur, Daniele Derlein, Ying Liu, Ciera Cobb, Olivia Masiewicz, Jennifer Mule, Michael Morsillo, Ella Hilt, Lisbeth Pennente, Bobbie Stubbeman, Alicia Garrido, Valeria Ravasi, Ioana Croitoru, Christos Koros, Nikolas Papagiannakis, Frank Ferrari, Mengyu Zheng, Shawna Reddie, Alicia Alejandra, Andrea Gray, Alejandra Valenzuela, Caitlin Goodman, Sara Dresler, Neil Santos, Fahrial Esha, Kyle Rizer, Nadine Zablith, Liliana Dumitrescu, Debra Galley, Victoria Kate Foster, Jamil Razzaque, Madita Grümmer, Yara Krasowski, Elisabeth Sittig, Oluwadamilola Ojo, Kelly Clark, Rory Mahabir, Kori Ribb, Shamera Willoughby   +145 more
wiley   +1 more source

Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. [PDF]

, 2019
PurposeCardiac autonomic dysfunction manifests as reduced heart rate variability (HRV) in idiopathic Parkinson's disease (PD), but no significant reduction has been found in PD patients who carry the LRRK2 mutation.
Carricarte Naranjo, Claudia, Cornforth, David J, Estévez, Mario, Goldman, Samuel M, Jelinek, Herbert F, Lang, Anthony E, Machado, Andrés, Marras, Connie, Sanchez-Rodriguez, Lazaro, Schüle, Birgitt, Stein, Phyllis K, Visanji, Naomi P   +11 more
core  

Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2 [PDF]

, 2020
Rab8a is associated with the dynamic regulation of membrane protrusions in polarized cells. Rab8a is one of several Rab GTPases that are substrates of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that is linked to Parkinson's disease ...
Alessi, Dario R., Khan, Amir R., McGrath, Emma, Pal, Prosenjit, Purlyte, Elena, Waschbüsch, Dieter   +5 more
core   +3 more sources

Aberrant Patterns of Sensory-Evoked Activity in the Olfactory Bulb of LRRK2 Knockout Mice

Cells, 2021
The LRRK2 gene is the major genetic determinant of familiar Parkinson’s disease (PD). Leucine-rich repeat kinase 2 (LRRK2) is a multidomain protein involved in several intracellular signaling pathways.
Andrea Maset, Marco Albanesi, Antonio di Soccio, Martina Canova, Marco dal Maschio, Claudia Lodovichi   +5 more
doaj   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls [PDF]

, 2019
BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would
Aasly, Jan, Agalliu, llir, Alcalay, Roy N., Berg, Daniela, Bressman, Susan, Brockmann, Kathrin, Foroud, Tatiana, Friedman, Eitan, Giladi, Nir, Glickman, Amanda, Hassin-Baer, Sharon, Inzelberg, Rivka, Marder, Karen, Mejia-Santana, Helen, Mirelman, Anat, Mondragon, Elisabet, Ortega, Roberto A., Pont-Sunyer, Claustre, Raymond, Deborah, Ruiz-Martinez, Javier, San Luciano, Marta, Saunders-Pullman, Rachel, Tolosa, Eduardo, Vilas, Dolores, Warø, Bjørg   +24 more
core   +1 more source

The emerging role of LRRK2 in tauopathies

Clinical Science, 2022
Abstract Parkinson’s disease (PD) is conventionally described as an α-synuclein aggregation disorder, defined by Lewy bodies and neurites, and mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common autosomal dominant cause of PD. However, LRRK2 mutations may be associated with diverse pathologies in patients with Parkinson’
Susanne Herbst, Patrick A. Lewis, Huw R. Morris   +2 more
openaire   +3 more sources